Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Diabetic retinopathy (DR) remains the leading cause of blindness among working-age individuals in developed countries. Current treatments for DR are indicated in advanced stages of the disease and are associated with significant adverse effects. Therefore, new pharmacological treatments for the early stages of DR are needed. DR has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR, which participates in the microcirculatory abnormalities that occur in DR. Therefore, the study of the underlying mechanisms that lead to neurodegeneration will be essential for identifying new therapeutic targets. From the clinical point of view, the identification of those patients in whom retinal neurodegeneration appears will be crucial for implementing early treatment based on neuroprotective drugs. When the early stages of DR are the therapeutic target, it would be inconceivable to recommend an aggressive treatment such as intravitreous injections. By contrast, topical administration of neuroprotective drugs by using eye drops is a possible option. However, clinical trials to determine the safety and effectiveness of this non-invasive route, as well as a standardisation of the methods for monitoring neurodegeneration, are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden
Heintz, E., Wiréhn, A.-B., Peebo, B. B., Rosenqvist, U., & Levin, L.-Å. (2010) · Diabetologia · doi:10.1007/s00125-010-1836-3 · Cited by 107 · cited 1×
“5 Notably, average healthcare costs increase considerably with the severity of DR, which suggests that preventing the progression of DR may alleviate the economic burden related to this complication of diabetes.(6) Current treatments for DR (laser photocoagulation, intravitreal corticosteroids, intravitreal antivascul…”
Background
Cited by
Neurodegeneration in diabetic retinopathy: does it really matter?
Simó, R., Stitt, A. W., & Gardner, T. W. (2018) · Diabetologia · doi:10.1007/s00125-018-4692-1 · Cited by 591
Self-citationNeurodegeneration in the diabetic eye: new insights and therapeutic perspectives
Simó, R., & Hernández, C. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.005 · Cited by 490
Self-citationHernández, C., Bogdanov, P., Corraliza, L., García-Ramírez, M., Solà-Adell, C., Arranz, J. A., Arroba, A. I., Valverde, A. M., & Simó, R. (2016) · Diabetes · doi:10.2337/db15-0443 · Cited by 267
“In other words, retinal neurodegeneration is an early event in the pathogenesis of DR (3-5).”
Self-citationTargeting the complement system for the management of retinal inflammatory and degenerative diseases
Xu, H., & Chen, M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.001 · Cited by 160
“There is growing evidence to suggest that retinal neuron damage, in particular the reactive oxygen species (ROS) released by stressed photoreceptors is an early event in DR pathogenesis (Du et al., 2013; Simo et al., 2012).”
BackgroundGLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó, R., & Hernández, C. (2017) · Diabetes · doi:10.2337/db16-1364 · Cited by 86
Self-citation
Metadata
- Authors
- Simó, R., Hernández, C., & on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)*
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2012-08-11
- Volume
- 96
- Issue
- 10
- Pages
- 1285-1290
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2160241739
- Cited by
- 150
- References
- 4
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. https://app.cochat.ai/papers/10.1136/bjophthalmol-2012-302005
- The paper
- Simó, R., Hernández, C., & on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)*. (2012). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2012-302005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.